OM 8980

Known as: OM-8980

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.

2004

SummaryA total of 95 patients suffering from active rheumatoid arthritis were included in this double-blind, placebo-controlled…

1994

OM-8980 is a slow-acting antirheumatic drug (SAARD). It is a glycoprotein extract of Escherichia coli, with immunomodulatory…

1993

Sixty patients with active RA were evaluated over 6 months in a double-blind randomized dose range multicentre study comparing…

Review

1993

Review

1993

The results obtained with Subreum®, a peptide extract of E. coli, given orally, as a slow acting antirheumatic drug are…

Review

1993

Review

1993

Although the pathogenesis of rheumatoid arthritis increasingly continues to be well understood, therapeutic approaches to the…

1991

OM-8980 is an immunomodulating drug which has been shown in double blind placebo controlled trials to be effective in the…

1990

Forty patients with active rheumatoid arthritis were included in this monocentre double-blind study comparing the therapeutic…

1990

SummaryA 6-month double-blind study of OM-8980 and auranofin in 145 patients with rheumatoid arthritis was followed by an open…

Highly Cited

1989

Highly Cited

1989

A new immunomodulating drug, OM-8980, was compared to placebo in a 6-month double blind multicenter trial including 107 patients…

1988

The therapeutic efficacy of the immunomodulator OM-8980 in rheumatoid arthritis was compared with that of auranofin, an oral gold…